Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Partial rescue of naturally occurring active site factor X variants through decreased inhibition by tissue factor pathway inhibitor and antithrombin.

Ahnström J, Gierula M, Temenu J, Laffan MA, Lane DA.

J Thromb Haemost. 2019 Aug 29. doi: 10.1111/jth.14627. [Epub ahead of print]

PMID:
31466141
2.

Germline mutations in the transcription factor IKZF5 cause thrombocytopenia.

Lentaigne C, Greene D, Sivapalaratnam S, Favier R, Seyres D, Thys C, Grassi L, Mangles S, Sibson K, Stubbs M, Burden F, Bordet JC, Armari-Alla C, Erber W, Farrow S, Gleadall N, Gomez K, Megy K, Papadia S, Penkett CJ, Sims MC, Stefanucci L, Stephens JC, Read RJ, Stirrups KE, Ouwehand WH, Laffan MA; NIHR BioResource, Frontini M, Freson K, Turro E.

Blood. 2019 Dec 5;134(23):2070-2081. doi: 10.1182/blood.2019000782.

PMID:
31217188
3.

Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders.

Downes K, Megy K, Duarte D, Vries M, Gebhart J, Hofer S, Shamardina O, Deevi SVV, Stephens J, Mapeta R, Tuna S, Al Hasso N, Besser MW, Cooper N, Daugherty L, Gleadall N, Greene D, Haimel M, Martin H, Papadia S, Revel-Vilk S, Sivapalaratnam S, Symington E, Thomas W, Thys C, Tolios A, Penkett CJ; NIHR BioResource, Ouwehand WH, Abbs S, Laffan MA, Turro E, Simeoni I, Mumford AD, Henskens YMC, Pabinger I, Gomez K, Freson K.

Blood. 2019 Dec 5;134(23):2082-2091. doi: 10.1182/blood.2018891192.

PMID:
31064749
4.

The heparin binding domain of von Willebrand factor binds to growth factors and promotes angiogenesis in wound healing.

Ishihara J, Ishihara A, Starke RD, Peghaire CR, Smith KE, McKinnon TAJ, Tabata Y, Sasaki K, White MJV, Fukunaga K, Laffan MA, Lutolf MP, Randi AM, Hubbell JA.

Blood. 2019 Jun 13;133(24):2559-2569. doi: 10.1182/blood.2019000510. Epub 2019 Apr 11.

PMID:
30975637
5.

Phenotype description and response to thrombopoietin receptor agonist in DIAPH1-related disorder.

Westbury SK, Downes K, Burney C, Lozano ML, Obaji SG, Toh CH, Sevivas T, Morgan NV, Erber WN, Kempster C, Moore SF, Thys C, Papadia S, Ouwehand WH; NIHR BioResource–Rare Diseases, Laffan MA, Gomez K, Freson K, Rivera J, Mumford AD.

Blood Adv. 2018 Sep 25;2(18):2341-2346. doi: 10.1182/bloodadvances.2018020370. No abstract available.

6.

Clinical bleeding and thrombin generation in admissions to critical care with prolonged prothrombin time: an exploratory study.

Stanworth SJ, Desborough MJR, Simons G, Seeney F, Powter G, MacDonald S, McKechnie S, Green L, Young N, Walsh T, Laffan MA.

Transfusion. 2018 Jun;58(6):1388-1398. doi: 10.1111/trf.14605. Epub 2018 Apr 10.

PMID:
29637582
7.

Corrigendum: Drug therapy in anticoagulation: which drug for which patient?

Millar CM, Laffan MA.

Clin Med (Lond). 2017 Jul;17(4):347-349. doi: 10.7861/clinmedicine.17-4-347a. No abstract available.

8.

The Effect of Iron Status on Risk of Coronary Artery Disease: A Mendelian Randomization Study-Brief Report.

Gill D, Del Greco M F, Walker AP, Srai SKS, Laffan MA, Minelli C.

Arterioscler Thromb Vasc Biol. 2017 Sep;37(9):1788-1792. doi: 10.1161/ATVBAHA.117.309757. Epub 2017 Jul 6.

9.

Expanded repertoire of RASGRP2 variants responsible for platelet dysfunction and severe bleeding.

Westbury SK, Canault M, Greene D, Bermejo E, Hanlon K, Lambert MP, Millar CM, Nurden P, Obaji SG, Revel-Vilk S, Van Geet C, Downes K, Papadia S, Tuna S, Watt C; NIHR BioResource–Rare Diseases Consortium, Freson K, Laffan MA, Ouwehand WH, Alessi MC, Turro E, Mumford AD.

Blood. 2017 Aug 24;130(8):1026-1030. doi: 10.1182/blood-2017-03-776773. Epub 2017 Jun 21.

10.

Drug therapy in anticoagulation: which drug for which patient?

Millar CM, Laffan MA.

Clin Med (Lond). 2017 Jun;17(3):233-244. doi: 10.7861/clinmedicine.17-3-233. Erratum in: Clin Med (Lond). 2017 Jul;17 (4):347-349. Dosage error in article text.

11.

ADAMTS-13 glycans and conformation-dependent activity.

Nowak AA, O'Brien HER, Henne P, Doerr A, Vanhoorelbeke K, Laffan MA, McKinnon TAJ.

J Thromb Haemost. 2017 Jun;15(6):1155-1166. doi: 10.1111/jth.13688. Epub 2017 Apr 27.

12.

Rare variants in GP1BB are responsible for autosomal dominant macrothrombocytopenia.

Sivapalaratnam S, Westbury SK, Stephens JC, Greene D, Downes K, Kelly AM, Lentaigne C, Astle WJ, Huizinga EG, Nurden P, Papadia S, Peerlinck K, Penkett CJ, Perry DJ, Roughley C, Simeoni I, Stirrups K, Hart DP, Tait RC, Mumford AD; NIHR BioResource, Laffan MA, Freson K, Ouwehand WH, Kunishima S, Turro E.

Blood. 2017 Jan 26;129(4):520-524. doi: 10.1182/blood-2016-08-732248. Epub 2016 Nov 14.

13.

A low balance between microparticles expressing tissue factor pathway inhibitor and tissue factor is associated with thrombosis in Behçet's Syndrome.

Khan E, Ambrose NL, Ahnström J, Kiprianos AP, Stanford MR, Eleftheriou D, Brogan PA, Mason JC, Johns M, Laffan MA, Haskard DO.

Sci Rep. 2016 Dec 7;6:38104. doi: 10.1038/srep38104.

14.

Von Willebrand factor and angiogenesis: basic and applied issues.

Randi AM, Laffan MA.

J Thromb Haemost. 2017 Jan;15(1):13-20. doi: 10.1111/jth.13551. Review.

15.

Dietary supplement use and nosebleeds in hereditary haemorrhagic telangiectasia - an observational study.

Chamali B, Finnamore H, Manning R, Laffan MA, Hickson M, Whelan K, Shovlin CL.

Intractable Rare Dis Res. 2016 May;5(2):109-13. doi: 10.5582/irdr.2016.01019.

16.

Inherited platelet disorders: toward DNA-based diagnosis.

Lentaigne C, Freson K, Laffan MA, Turro E, Ouwehand WH; BRIDGE-BPD Consortium and the ThromboGenomics Consortium.

Blood. 2016 Jun 9;127(23):2814-23. doi: 10.1182/blood-2016-03-378588. Epub 2016 Apr 19. Review.

17.

A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders.

Simeoni I, Stephens JC, Hu F, Deevi SV, Megy K, Bariana TK, Lentaigne C, Schulman S, Sivapalaratnam S, Vries MJ, Westbury SK, Greene D, Papadia S, Alessi MC, Attwood AP, Ballmaier M, Baynam G, Bermejo E, Bertoli M, Bray PF, Bury L, Cattaneo M, Collins P, Daugherty LC, Favier R, French DL, Furie B, Gattens M, Germeshausen M, Ghevaert C, Goodeve AC, Guerrero JA, Hampshire DJ, Hart DP, Heemskerk JW, Henskens YM, Hill M, Hogg N, Jolley JD, Kahr WH, Kelly AM, Kerr R, Kostadima M, Kunishima S, Lambert MP, Liesner R, López JA, Mapeta RP, Mathias M, Millar CM, Nathwani A, Neerman-Arbez M, Nurden AT, Nurden P, Othman M, Peerlinck K, Perry DJ, Poudel P, Reitsma P, Rondina MT, Smethurst PA, Stevenson W, Szkotak A, Tuna S, van Geet C, Whitehorn D, Wilcox DA, Zhang B, Revel-Vilk S, Gresele P, Bellissimo DB, Penkett CJ, Laffan MA, Mumford AD, Rendon A, Gomez K, Freson K, Ouwehand WH, Turro E.

Blood. 2016 Jun 9;127(23):2791-803. doi: 10.1182/blood-2015-12-688267. Epub 2016 Apr 15.

18.

Defects in TRPM7 channel function deregulate thrombopoiesis through altered cellular Mg(2+) homeostasis and cytoskeletal architecture.

Stritt S, Nurden P, Favier R, Favier M, Ferioli S, Gotru SK, van Eeuwijk JM, Schulze H, Nurden AT, Lambert MP, Turro E, Burger-Stritt S, Matsushita M, Mittermeier L, Ballerini P, Zierler S, Laffan MA, Chubanov V, Gudermann T, Nieswandt B, Braun A.

Nat Commun. 2016 Mar 29;7:11097. doi: 10.1038/ncomms11097.

19.

A dominant gain-of-function mutation in universal tyrosine kinase SRC causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies.

Turro E, Greene D, Wijgaerts A, Thys C, Lentaigne C, Bariana TK, Westbury SK, Kelly AM, Selleslag D, Stephens JC, Papadia S, Simeoni I, Penkett CJ, Ashford S, Attwood A, Austin S, Bakchoul T, Collins P, Deevi SV, Favier R, Kostadima M, Lambert MP, Mathias M, Millar CM, Peerlinck K, Perry DJ, Schulman S, Whitehorn D, Wittevrongel C; BRIDGE-BPD Consortium, De Maeyer M, Rendon A, Gomez K, Erber WN, Mumford AD, Nurden P, Stirrups K, Bradley JR, Raymond FL, Laffan MA, Van Geet C, Richardson S, Freson K, Ouwehand WH.

Sci Transl Med. 2016 Mar 2;8(328):328ra30. doi: 10.1126/scitranslmed.aad7666. Epub 2016 Mar 2.

20.

A gain-of-function variant in DIAPH1 causes dominant macrothrombocytopenia and hearing loss.

Stritt S, Nurden P, Turro E, Greene D, Jansen SB, Westbury SK, Petersen R, Astle WJ, Marlin S, Bariana TK, Kostadima M, Lentaigne C, Maiwald S, Papadia S, Kelly AM, Stephens JC, Penkett CJ, Ashford S, Tuna S, Austin S, Bakchoul T, Collins P, Favier R, Lambert MP, Mathias M, Millar CM, Mapeta R, Perry DJ, Schulman S, Simeoni I, Thys C; BRIDGE-BPD Consortium, Gomez K, Erber WN, Stirrups K, Rendon A, Bradley JR, van Geet C, Raymond FL, Laffan MA, Nurden AT, Nieswandt B, Richardson S, Freson K, Ouwehand WH, Mumford AD.

Blood. 2016 Jun 9;127(23):2903-14. doi: 10.1182/blood-2015-10-675629. Epub 2016 Feb 24.

21.

Site-specific analysis of von Willebrand factor O-glycosylation.

Solecka BA, Weise C, Laffan MA, Kannicht C.

J Thromb Haemost. 2016 Apr;14(4):733-46. doi: 10.1111/jth.13260. Epub 2016 Feb 17.

22.

Human phenotype ontology annotation and cluster analysis to unravel genetic defects in 707 cases with unexplained bleeding and platelet disorders.

Westbury SK, Turro E, Greene D, Lentaigne C, Kelly AM, Bariana TK, Simeoni I, Pillois X, Attwood A, Austin S, Jansen SB, Bakchoul T, Crisp-Hihn A, Erber WN, Favier R, Foad N, Gattens M, Jolley JD, Liesner R, Meacham S, Millar CM, Nurden AT, Peerlinck K, Perry DJ, Poudel P, Schulman S, Schulze H, Stephens JC, Furie B, Robinson PN, van Geet C, Rendon A, Gomez K, Laffan MA, Lambert MP, Nurden P, Ouwehand WH, Richardson S, Mumford AD, Freson K; BRIDGE-BPD Consortium.

Genome Med. 2015 Apr 9;7(1):36. doi: 10.1186/s13073-015-0151-5. eCollection 2015.

23.

PARP-14 combines with tristetraprolin in the selective posttranscriptional control of macrophage tissue factor expression.

Iqbal MB, Johns M, Cao J, Liu Y, Yu SC, Hyde GD, Laffan MA, Marchese FP, Cho SH, Clark AR, Gavins FN, Woollard KJ, Blackshear PJ, Mackman N, Dean JL, Boothby M, Haskard DO.

Blood. 2014 Dec 4;124(24):3646-55. doi: 10.1182/blood-2014-07-588046. Epub 2014 Oct 7.

24.

The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology.

Laffan MA, Lester W, O'Donnell JS, Will A, Tait RC, Goodeve A, Millar CM, Keeling DM.

Br J Haematol. 2014 Nov;167(4):453-65. doi: 10.1111/bjh.13064. Epub 2014 Aug 12. Review. No abstract available.

25.

Randomised trials of human albumin for adults with sepsis: systematic review and meta-analysis with trial sequential analysis of all-cause mortality.

Patel A, Laffan MA, Waheed U, Brett SJ.

BMJ. 2014 Jul 22;349:g4561. doi: 10.1136/bmj.g4561. Review. Erratum in: BMJ. 2014;349:g4850.

26.

Ischaemic strokes in patients with pulmonary arteriovenous malformations and hereditary hemorrhagic telangiectasia: associations with iron deficiency and platelets.

Shovlin CL, Chamali B, Santhirapala V, Livesey JA, Angus G, Manning R, Laffan MA, Meek J, Tighe HC, Jackson JE.

PLoS One. 2014 Feb 19;9(2):e88812. doi: 10.1371/journal.pone.0088812. eCollection 2014.

27.

The O-linked glycans of human von Willebrand factor modulate its interaction with ADAMTS-13.

Nowak AA, McKinnon TA, Hughes JM, Chion AC, Laffan MA.

J Thromb Haemost. 2014 Jan;12(1):54-61. doi: 10.1111/jth.12451.

28.

The von Willebrand factor predicted unpaired cysteines are essential for secretion.

Shapiro SE, Nowak AA, Wooding C, Birdsey G, Laffan MA, McKinnon TA.

J Thromb Haemost. 2014 Feb;12(2):246-54. doi: 10.1111/jth.12466.

29.

Von Willebrand factor, angiodysplasia and angiogenesis.

Randi AM, Laffan MA, Starke RD.

Mediterr J Hematol Infect Dis. 2013 Sep 2;5(1):e2013060. doi: 10.4084/MJHID.2013.060. Review.

30.

Transfusion for acute upper gastrointestinal bleeding.

Patel A, Laffan MA.

N Engl J Med. 2013 Apr 4;368(14):1362. doi: 10.1056/NEJMc1301256. No abstract available.

PMID:
23550680
31.

Cellular and molecular basis of von Willebrand disease: studies on blood outgrowth endothelial cells.

Starke RD, Paschalaki KE, Dyer CE, Harrison-Lavoie KJ, Cutler JA, McKinnon TA, Millar CM, Cutler DF, Laffan MA, Randi AM.

Blood. 2013 Apr 4;121(14):2773-84. doi: 10.1182/blood-2012-06-435727. Epub 2013 Jan 25.

32.

Clinical phenotype, laboratory features and genotype of 35 patients with heritable dysfibrinogenaemia.

Shapiro SE, Phillips E, Manning RA, Morse CV, Murden SL, Laffan MA, Mumford AD.

Br J Haematol. 2013 Jan;160(2):220-7. doi: 10.1111/bjh.12085. Epub 2012 Oct 15.

PMID:
23061815
33.

Mapping the N-glycome of human von Willebrand factor.

Canis K, McKinnon TA, Nowak A, Haslam SM, Panico M, Morris HR, Laffan MA, Dell A.

Biochem J. 2012 Oct 15;447(2):217-28.

34.

Characterisation of von Willebrand factor A1 domain mutants I1416N and I1416T: correlation of clinical phenotype with flow-based platelet adhesion.

McKinnon TA, Nowak AA, Cutler J, Riddell AF, Laffan MA, Millar CM.

J Thromb Haemost. 2012 Jul;10(7):1409-16. doi: 10.1111/j.1538-7836.2012.04760.x.

35.

O-linked glycosylation of von Willebrand factor modulates the interaction with platelet receptor glycoprotein Ib under static and shear stress conditions.

Nowak AA, Canis K, Riddell A, Laffan MA, McKinnon TA.

Blood. 2012 Jul 5;120(1):214-22. doi: 10.1182/blood-2012-02-410050. Epub 2012 Apr 19.

PMID:
22517896
36.

Low serum iron levels are associated with elevated plasma levels of coagulation factor VIII and pulmonary emboli/deep venous thromboses in replicate cohorts of patients with hereditary haemorrhagic telangiectasia.

Livesey JA, Manning RA, Meek JH, Jackson JE, Kulinskaya E, Laffan MA, Shovlin CL.

Thorax. 2012 Apr;67(4):328-33. doi: 10.1136/thoraxjnl-2011-201076. Epub 2011 Dec 14.

PMID:
22169361
37.

Pregnancy in type 2B VWD: a case series.

Ranger A, Manning RA, Lyall H, Laffan MA, Millar CM.

Haemophilia. 2012 May;18(3):406-12. doi: 10.1111/j.1365-2516.2011.02691.x. Epub 2011 Nov 14.

PMID:
22077376
38.

Safety of recombinant activated factor VII in randomized clinical trials.

Patel A, Cooper N, Laffan MA.

N Engl J Med. 2011 Feb 10;364(6):574; author reply 575-6. doi: 10.1056/NEJMc1013591. No abstract available.

PMID:
21306250
39.

Endothelial von Willebrand factor regulates angiogenesis.

Starke RD, Ferraro F, Paschalaki KE, Dryden NH, McKinnon TA, Sutton RE, Payne EM, Haskard DO, Hughes AD, Cutler DF, Laffan MA, Randi AM.

Blood. 2011 Jan 20;117(3):1071-80. doi: 10.1182/blood-2010-01-264507. Epub 2010 Nov 3.

40.

Specific N-linked glycosylation sites modulate synthesis and secretion of von Willebrand factor.

McKinnon TA, Goode EC, Birdsey GM, Nowak AA, Chan AC, Lane DA, Laffan MA.

Blood. 2010 Jul 29;116(4):640-8. doi: 10.1182/blood-2010-02-267450. Epub 2010 Apr 23.

PMID:
20418283
41.

Monitoring heparin anticoagulation in the acute phase response.

Uprichard J, Manning RA, Laffan MA.

Br J Haematol. 2010 May;149(4):613-9. doi: 10.1111/j.1365-2141.2010.08129.x. Epub 2010 Mar 11.

PMID:
20230412
42.

Endothelial cell processing and alternatively spliced transcripts of factor VIII: potential implications for coagulation cascades and pulmonary hypertension.

Shovlin CL, Angus G, Manning RA, Okoli GN, Govani FS, Elderfield K, Birdsey GM, Mollet IG, Laffan MA, Mauri FA.

PLoS One. 2010 Feb 11;5(2):e9154. doi: 10.1371/journal.pone.0009154.

43.

Expression of terminal alpha2-6-linked sialic acid on von Willebrand factor specifically enhances proteolysis by ADAMTS13.

McGrath RT, McKinnon TA, Byrne B, O'Kennedy R, Terraube V, McRae E, Preston RJ, Laffan MA, O'Donnell JS.

Blood. 2010 Apr 1;115(13):2666-73. doi: 10.1182/blood-2009-09-241547. Epub 2009 Nov 24.

PMID:
19965639
44.

Haemopoietic stem cell transplantation induces tolerance to donor antigens but not to foreign FVIII peptides.

Uprichard J, Dazzi F, Apperley JF, Laffan MA.

Haemophilia. 2010 Jan;16(1):143-7. doi: 10.1111/j.1365-2516.2009.02099.x. Epub 2009 Sep 4.

PMID:
19735311
45.

Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von Willebrand factor.

Riddell AF, Gomez K, Millar CM, Mellars G, Gill S, Brown SA, Sutherland M, Laffan MA, McKinnon TA.

Blood. 2009 Oct 15;114(16):3489-96. doi: 10.1182/blood-2008-10-184317. Epub 2009 Aug 17.

PMID:
19687512
46.

A novel binding site for ADAMTS13 constitutively exposed on the surface of globular VWF.

Zanardelli S, Chion AC, Groot E, Lenting PJ, McKinnon TA, Laffan MA, Tseng M, Lane DA.

Blood. 2009 Sep 24;114(13):2819-28. doi: 10.1182/blood-2009-05-224915. Epub 2009 Jul 8.

47.

Acute myocardial infarction following tranexamic acid use in a low cardiovascular risk setting.

Sirker A, Malik N, Bellamy M, Laffan MA.

Br J Haematol. 2008 Jun;141(6):907-8. doi: 10.1111/j.1365-2141.2008.07128.x. Epub 2008 Mar 19. No abstract available.

PMID:
18355380
48.

N-linked glycosylation of VWF modulates its interaction with ADAMTS13.

McKinnon TA, Chion AC, Millington AJ, Lane DA, Laffan MA.

Blood. 2008 Mar 15;111(6):3042-9. Epub 2007 Nov 1.

PMID:
17975018
49.

Efficacy of recombinant activated factor VII in unselected patients with uncontrolled haemorrhage: a single centre experience.

Payne EM, Brett SJ, Laffan MA.

Blood Coagul Fibrinolysis. 2006 Jul;17(5):397-402.

PMID:
16788316
50.

Effect of L-carnitine administration on erythrocyte survival in haemodialysis patients.

Arduini A, Bonomini M, Clutterbuck EJ, Laffan MA, Pusey CD.

Nephrol Dial Transplant. 2006 Sep;21(9):2671-2. Epub 2006 Apr 12. No abstract available.

PMID:
16611680

Supplemental Content

Loading ...
Support Center